Mounjaro Doses: FDA-Label Range and Titration Basics

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

People searching "Mounjaro doses" usually want to understand the shape of the dosing structure, not a personal schedule. This overview reports what the FDA label documents about the range and format, explains why the class is titrated gradually, and points to the conversations that belong with a clinician. It prescribes nothing. For related material, see the PlexusDx Education Hub.

What the FDA label documents

Per the Mounjaro FDA label, the structure begins at a 2.5 mg starting dose, with maintenance doses up to 15 mg per week per the current FDA label. Mounjaro is administered as a once-weekly subcutaneous injection. The label frames a graduated titration concept: begin at the lowest dose so the body can adapt to GLP-1 pathway activation, then adjust upward under prescriber supervision according to tolerability and response.

The once-weekly format

Mounjaro's once-weekly subcutaneous format is part of what defines the patient experience. The full administration protocol, including timing, storage, and technique where applicable, lives in the FDA label and the patient information leaflet that ships with the medication. A prescriber and pharmacist walk each patient through those details, which is why this page reports the format rather than instructing on it.

Why titration exists

Gradual titration is standard across the GLP-1 class for a concrete reason: gastrointestinal side effects, nausea most of all, tend to peak during dose escalation. The label's stepwise schedule is built to soften those symptoms while keeping therapeutic momentum. Real-world data associate skipped or accelerated titration with higher discontinuation rates, so the slow ramp is a tolerability strategy, not an arbitrary delay.

Individualization is the point

Dose selection, titration speed, and any adjustments are individualized clinical decisions rather than fixed numbers a reader can self-apply. Because response and tolerability differ from person to person, the label describes a range and a concept, leaving the specifics to a prescriber who knows the full picture. That is the difference between reporting label facts and giving dosing instructions.

What to raise with your provider

Conversations about Mounjaro dosing typically cover baseline metabolic status, kidney function, gastrointestinal history, prior medication tolerability, and the FDA-approved indication the prescription is written for. Never adjust GLP-1 receptor agonist dosing on your own. Bringing these topics to an appointment helps a provider tailor the graduated approach the label describes to an individual situation.

The genetic context upstream of dosing

Before any dose is chosen, biology is already in play. Variants in GIPR, GLP1R, and FTO sit upstream of a GLP-1 protocol and shape baseline appetite regulation, satiety signaling, and incretin response. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across that terrain. It does not predict dose response or titration tolerability; it provides context for the broader protocol conversation. PlexusDx offers tirzepatide through its Weight Management Protocols, including Tirzepatide Injection.

Reporting versus prescribing

It is worth restating the boundary this page keeps. Describing the range and format documented on the FDA label is reporting; choosing a specific dose, cadence, or adjustment for a person is prescribing, and only a clinician who knows your history can do that. Delivery formats and pen designs also differ across products and can change over time, and the patient information leaflet packaged with the medication governs the specifics for the exact product dispensed. If anything in that leaflet differs from a general summary, the leaflet and your prescriber are the authorities to follow, not a web overview. This distinction is not a formality. A dose that suits one person can be wrong for another with different metabolic status, kidney function, or gastrointestinal history, which is precisely why the label frames a range and a titration concept rather than a single instruction that a reader could safely apply without clinical oversight.

Frequently Asked Questions

What dosing range does the Mounjaro label describe?

Per the Mounjaro FDA label, the range runs from a 2.5 mg starting dose to maintenance doses up to 15 mg per week. The label describes a graduated titration approach. Specific dose selection and titration speed are individualized clinical decisions, so always follow the schedule a prescriber sets rather than adjusting on your own.

How is Mounjaro administered?

Mounjaro is administered as a once-weekly subcutaneous injection. The complete administration protocol, covering timing, storage, and technique where applicable, appears in the FDA label and the patient information leaflet included with the medication. A prescriber and pharmacist review those steps, which is why this overview reports the format instead of demonstrating it.

Why does Mounjaro use a titration schedule?

Titration reduces gastrointestinal side effects such as nausea, vomiting, and diarrhea that are most pronounced during dose escalation. The graduated schedule lets the body adapt to GLP-1 pathway activation and improves tolerability. Real-world data link skipped titration to higher discontinuation rates, which is why the ramp is deliberately gradual.

Does the genetic test predict my dose response?

No. The Precision Peptide Genetic Test does not predict Mounjaro dose response or titration tolerability. It analyzes pathway-level variants in genes such as GIPR that shape baseline GLP-1 biology, offering context for a broader protocol conversation with a healthcare provider rather than a dose-selection tool.

Explore more label-informed education at the PlexusDx Education Hub.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.